Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Brokerages

Shares of Catalent, Inc. (NYSE:CTLT) have been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating. The average 12 month target price among brokerages that have covered the stock in the last year is $63.40.

CTLT has been the topic of a number of analyst reports. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com began coverage on shares of Catalent in a research note on Friday. They issued a “hold” rating on the stock. Robert W. Baird restated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th.

Insider Activity

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in shares of Catalent by 15.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,520,308 shares of the company’s stock worth $92,085,000 after purchasing an additional 199,427 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new position in shares of Catalent during the 3rd quarter valued at $8,480,000. Tidal Investments LLC purchased a new stake in shares of Catalent during the 3rd quarter valued at about $214,000. Neo Ivy Capital Management acquired a new position in Catalent in the 3rd quarter worth $1,078,000. Finally, Nomura Asset Management Co. Ltd. lifted its position in shares of Catalent by 1.4% during the third quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock worth $3,211,000 after purchasing an additional 750 shares during the last quarter.

Catalent Stock Performance

Shares of NYSE:CTLT opened at $63.48 on Friday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent has a 52-week low of $41.15 and a 52-week high of $63.50. The business has a 50-day moving average price of $60.76 and a 200-day moving average price of $59.49. The stock has a market cap of $11.52 billion, a price-to-earnings ratio of -28.09, a PEG ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.10) earnings per share. Equities analysts predict that Catalent will post 0.78 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.